Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Hidradenitis Suppurativa Common in Patients with SpA

Semin Arthritis Rheum; 2019 Feb; Rondags, Arends, et al

In a cohort of axial spondyloarthritis (SpA) patients, hidradenitis suppurativa (HS) is more prevalent than in the general population (9.1% vs 0.053–4.1%), according to a recent study. Furthermore, HS is associated with female gender, lower quality of life (QOL), and especially higher axial SpA disease activity. A self-screening questionnaire based on validated diagnostic HS questions was sent to all participating axial SpA patients. Self-reported HS symptoms were confirmed by previous medical diagnosis or verification by phone using highly specific validated questions. Researchers found:

  • In total, 75.6% (449/592) questionnaires were eligible for analyses.
  • Included patients had a mean age of 50±13 years, 64% were male, mean symptom duration was 23±13 years, and 79% were HLA-B27 positive.
  • HS diagnosis could be confirmed in 41 patients, resulting in an estimated prevalence of 9.1%.
  • In comparison to patients without a positive history of HS, these patients were more often female (54% vs 35%), showed higher axial SpA disease activity, and worse QOL.
  • Also, a history of heel enthesitis and dactylitis was more prevalent (34% vs 19%, and 15% vs 6%, respectively).

Rondags A, Arends S, Wink FR, Horváth B, Spoorenberg A. High prevalence of hidradenitis suppurativa symptoms in axial spondyloarthritis patients: A possible new extra-articular manifestation. Semin Arthritis Rheum. 2019;48(4):611-617. doi:10.1016/j.semarthrit.2018.03.010